APP gets OK for chemo drug

SCHAUMBURG - APP Pharmaceuticals, Inc., a subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., announced Monday that it has received approval from the U.S. Food and Drug Administration to market idarubicin hydrochloride injection, the foundation of many chemotherapy regimens and for use as a therapy in patients with acute myeloid leukemia. Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by Pfizer Inc. APP expects to launch the drug in September.